Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu
Trial record 1 of 1 for:    NCT00382837
Previous Study | Return to List | Next Study

Study of Epratuzumab in Systemic Lupus Erythematosus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00382837
Recruitment Status : Withdrawn
First Posted : October 2, 2006
Last Update Posted : May 21, 2014
Information provided by:
UCB Pharma

Brief Summary:
Epratuzumab is an investigational antibody designed to help treat SLE. The purpose is to evaluate safety and long term efficacy in concert with standard SLE treatments

Condition or disease Intervention/treatment Phase
Systemic Lupus Erythematosus Drug: Epratuzumab Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III Multi-Center, OpenLabel, Follow-Up Study to Assess the Safety & Efficacy of Epratuzumab in Patients With Acute Severe SLE Flares Excluding the Renal or Neurologic Systems
Study Start Date : January 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lupus

Primary Outcome Measures :
  1. The primary objective is to continue to gather long term safety data on patients with moderate to severe flaring SLE.

Secondary Outcome Measures :
  1. To continue to assess the efficacy and tolerability of epratuzumab;
  2. To continue to monitor the plasma concentration and immunogenicity profile of epratuzumab in patients with Lupus;
  3. To continue to assess epratuzumab on Health-related quality of life in lupus patients;
  4. To continue to assess disease status as reported by the patient and physician.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must have completed SL0003 Alleviate A through 48 weeks

Exclusion Criteria:

  • Development of toxicity to Epratuzumab
  • Significant protocol deviations from SL0003 Study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00382837

Show Show 54 study locations
Sponsors and Collaborators
UCB Pharma
Layout table for investigator information
Study Director: Anna Barry UCB Pharma
Layout table for additonal information Identifier: NCT00382837    
Other Study ID Numbers: SL0005
EudraCT# 2006-003865-15
First Posted: October 2, 2006    Key Record Dates
Last Update Posted: May 21, 2014
Last Verified: March 2007
Keywords provided by UCB Pharma:
B-Cell immunotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents